The Office for Research Services (ORS), Division of Occupational Health and Safety (DOHS) is the organization responsible for the mandatory registration of research involving human, animal and plant pathogens and recombinant nucleic acid molecules within the NIH intramural program. Principal Investigators (PIs) are responsible for registering bacteria, virus, toxins of biological origin, and/or recombinant DNA.
To manage the registration program, DOHS uses
PI-Dashboard , a web-based system for submitting required research registrations and amendments. PI-Dashboard can be used securely from any computer with internet access. Through the PI-Dashboard system, researchers are able to register work with new material, amend approved registrations with the ability to add and remove labs, associated personnel, relevant linked registrations, and administrative details as needed.
Register Biological Material
Register Recombinant DNA
Amend an Existing Registration
Select Agent Program
NIH Office of Biotechnology Activities
Guide to the NIH Guidelines
At the NIH, exposure information for laboratory personnel is gathered with the Pathogen Registration Document (PRD) form. All Principal Investigators (PIs) working with human pathogens; human blood, body fluids, or tissues; animal pathogens; plant pathogens; biological toxins; and the blood, tissues, or body fluids of old-world non-human primate (NHP) species must submit a registration through PI-Dashboard. The registration will be reviewed by the NIH
Institutional Biosafety Committee (IBC).
back to the top
The initiation of any experiment involving recombinant DNA (rDNA) molecules requires review by the NIH IBC . PIs intending to work with rDNA must register their experiments through PI-Dashboard before experiments begin.
The NIH IBC, whose functions are defined under the
Guidelines, reviews and approves research protocols involving the use of rDNA techniques or potentially infectious/toxic materials. The IBC generally meets the first Wednesday of each month except for August. Refer to their
schedule for specific meeting dates and deadlines.
The NIH IBC determines the biosafety level based on a risk assessment including such factors as the agent in use, laboratory procedures, quantity of material being manipulated, etc. based on the
NIH Office of Science Policy.
It is the responsibility of the PI to provide the IBC with updated research information, as well as other changes to laboratory location and research personnel. It is required that the PI review all of their registration documents on an annual basis to ensure current and accurate information regarding their research. Amendments to current registrations and registrations submitted prior to July 2009 can be performed with
Administrative changes to personnel and laboratory location can be performed by the PI using PI-Dashboard. Changes that are made are reflected immediately. To make these changes PIs can highlight one of their registrations in their ‘My Research’ folder (shown on the left side of the page), and make changes to personnel, laboratory or associated registrations by right-clicking in the ‘Linked Records’ section on the right side of the page. Personnel and laboratory location selections are made by searching, then selecting out of a pre-populated NIH database. If your laboratory or personnel are not listed or cannot be found, please contact your
Safety and Health Specialist at (301) 496-2346.
Amendments to existing RD and PRD registrations such as adding new rDNA for a particular study, adding an Animal Study Proposal (ASP) to an existing RD, or updating the dual-use questionnaire, may also be performed under the ‘My Research’ folder by highlighting the registration in question, right-clicking and selecting the option ‘amend registration’. This process will create a time-stamped amendment file located in the ‘draft research registrations’ heading shown on the left hand side of the page.
The amendment page allows the PI to clearly describe the requested changes in a brief but complete narrative. All of the relevant aspects of the requested amendment should be discussed and all necessary documents (ASPs, amendments to ASPs, copies of vector maps, etc.) should be uploaded and submitted in the area at the bottom of the first page. Please keep in mind, the RD/PRD Dual-Use Screening Survey must be submitted with all such amendment requests and is located on the second page of the amendment request. In cases of ‘Joint Registrations’, where pathogenic agents are being used to perform rDNA experiments, only an amendment to the RD registration is necessary. 'Stand-alone’ PRD registrations (not associated with rDNA work) are amended when the nature of work with that agent changes (i.e., using the agent in a new study, adding an ASP, etc.).
For more information, please contact your Safety and Health Specialist at (301) 496-2346.
A research project is considered dual-use in nature if the methodologies, materials or results could be used for malevolent purposes, including harm to humans, animals and/or the environment. To ensure research performed at the NIH is conducted and published in a timely manner with due consideration given to experiments potentially having dual-use concerns, completing
RD/PRD Dual-Use Screening Survey Form is part of the electronic registration process. An affirmative answer will not delay the progress of research, but indicates that further review and consideration may be warranted as the research advances. Become familiar with the "dual-use" dilemma by completing a 30-minute module developed by the
Southeast Regional Center of Excellence for Emerging Infections and Biodefense(SERCEB).
Log in to
securely from any computer using your NIH username and password. Detailed instructions for how to submit registrations, submit amendments, and add registration proxies are located in the “Support Section”. Additionally, you can contact support personnel at (800) 690-3530 or
This outline is intended only to serve as a guide to the NIH Guidelines for Recombinant DNA Research. It is the responsibility of each NIH investigator to make sure that his/her laboratory is in compliance. Note that the vast majority of experiments involving recombinant DNA require registration and approval prior to, or simultaneous with, initiation (see below). A small number of experiments are exempt from registration BUT only the IBC can determine whether experiment(s) fall into this category. It is useful to consider the relevant section of the Guidelines under which your experiment(s) fall and review the recommendation for the appropriate biosafety level under which the experiment(s) would be conducted. However, only the IBC can establish the containment level.
For advice on how to complete the registration form or clarification of the Guidelines, contact the
Safety and Health Specialist at (301) 496-2346.
Section III-A & B – Experiments that require registration and NIH and IBC approval PRIOR to initiation:
Deliberate transfer of a drug resistance trait to microorganisms that are not known to acquire the trait naturally if such acquisition could compromise the use of the drug to control disease, or cloning of toxin genes with LD50 of less than 100 ng/kg body weight.
Section III-C – Experiments that require IBC and IRB approvals and RAC review PRIOR to research participant enrollment:
Experiments Involving the transfer of recombinant DNA or RNA derived from rDNA, into one or more human research participants. Experiments Involving the transfer of recombinant DNA or RNA derived from rDNA, into one or more human research participants.
Section III-D – Experiments that require registration & IBC approval PRIOR to initiation:
Experiments using Risk Group 2, 3, or 4 agents as host-vector systems. Experiments using Risk Group 2, 3, or 4 agents as host-vector systems.
Experiments in which DNA from Risk Group 2, 3, or 4 agents is cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector systems. Experiments in which DNA from Risk Group 2, 3, or 4 agents is cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector systems.
Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of Helper Virus in Tissue Culture Systems.
Experiments involving whole animals (with the exception of transgenic rodents requiring BSL-1 containment). Experiments involving whole animals (with the exception of transgenic rodents requiring BSL-1 containment).
Experiments involving whole plants. Experiments involving whole plants.
Experiments involving more than 10 liters of culture. Experiments involving more than 10 liters of culture.
Experiments involving human influenza strains H2N2, 1918 H1N1, and/or highly pathogenic H5N1.
Section III-E – Experiments that require IBC notice by registration simultaneous with initiation:
Experiments involving the formation of rDNA molecules containing no more than two-thirds of the genome of any eukaryotic virus.
Cloning in non-pathogenic prokaryotes and non-pathogenic lower eukaryotes.
Generation by embryo injection of transgenic rodents requiring BSL-1 containment.
Breeding 2 different transgenic strains of rodents to generate novel transgenic strains requiring only BSL-1 containment.
Experiments involving whole plants that require BSL-1 or BSL-2 containment.